Humalog Kwikpen (Insulin Lispro)

Humalog Kwikpen is indicated for the management of blood glucose in adults and children with diabetes who require rapid‑acting insulin.

• Mealtime (prandial) insulin coverage for type 1 diabetes mellitus.
• Mealtime insulin supplementation for type 2 diabetes mellitus when diet, exercise, and oral agents are insufficient.
• Correction of post‑prandial hyperglycemia in patients using basal insulin regimens.
• Use in insulin pump transition periods as a temporary rapid‑acting insulin source.
• Adjunct therapy in gestational diabetes when rapid insulin action is clinically indicated.

• Insulin lispro is a synthetic analogue of human insulin in which two amino acids are reversed, resulting in a molecule that is absorbed more rapidly after subcutaneous injection. The analogue binds to insulin receptors on muscle and adipose cells, activating the receptor’s intrinsic tyrosine‑kinase activity. This promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppresses hepatic glucose production, thereby lowering plasma glucose concentrations.

The most frequently reported adverse reactions to Humalog Kwikpen involve the injection site and systemic hypoglycaemia, while rare but serious events may affect the cardiovascular or immune systems.

Common

• Mild hypoglycaemia (blood glucose <70 mg/dL) with symptoms such as shakiness, sweating, or hunger.
• Injection‑site pain, redness, or swelling.
• Lipohypertrophy (localized thickening of subcutaneous tissue) at repeated injection sites.
• Allergic skin reactions, including rash or itching.
• Nausea or vomiting.

Serious

• Severe hypoglycaemia leading to loss of consciousness, seizures, or coma.
• Anaphylactic reaction characterized by difficulty breathing, swelling of the face or throat, and hives.
• Cardiovascular events such as angina or myocardial infarction possibly precipitated by rapid glucose shifts.
• Hypersensitivity leading to serum sickness‑like reaction with fever, arthralgia, and lymphadenopathy.

When using Humalog Kwikpen, patients and healthcare providers should observe several precautions to minimize risks and ensure optimal glycaemic control.

• Rotate injection sites within the same anatomical region to reduce lipohypertrophy and improve insulin absorption.
• Do not use the pen after the indicated expiration date or if the solution appears cloudy, discolored, or contains particles.
• Store the pen refrigerated (2‑8 °C) before first use; after opening, keep at ≤30 °C for up to 28 days.
• Monitor blood glucose closely during dose adjustments, illness, or changes in diet and physical activity.
• Patients with renal or hepatic impairment may require individualized dosing and more frequent glucose monitoring.

Humalog Kwikpen may interact with other medicines or substances that affect blood glucose levels or insulin action; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• Administration of beta‑blockers, which can mask hypoglycaemia symptoms.
• Use of high‑dose glucocorticoids that significantly raise blood glucose.

Use with caution

• Combination with oral antidiabetic agents (e.g., sulfonylureas, meglitinides) – monitor for additive hypoglycaemia.
• Concurrent use of ACE inhibitors or ARBs – may enhance insulin sensitivity, requiring glucose monitoring.
• Alcohol consumption – can cause delayed hypoglycaemia, especially when insulin dose is high.